Convalescent plasma anti SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization
Convalescent plasma anti SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization
复制标题
DOI：
10.1172/jci141206
复制
发表时间：
2020-12-01
影响因子：
15.9
通讯作者：
Musser, James M.
中科院分区：
文献类型：
--
作者：
Salazar, Eric;Kuchipudi, Suresh V.;Musser, James M.
新出现的严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）突出表明，迫切需要检测中和抗体的保护水平。我们利用68例COVID-19恢复期血浆样本，研究了抗刺突外结构域（anti-ECD）、抗受体结合结构域（anti-RBD） IgG滴度与SARS-CoV-2病毒中和（VN）滴度的关系。我们报告了血浆抗rbd和抗ecd IgG滴度与体外VN滴度之间的强正相关。当抗rbd或抗ecd滴度为>= 1:1350时，VN滴度为>= 80% （fda推荐用于COVID-19治疗的恢复期血浆水平）的概率为>= 80%。在所有献血者中，37%的人缺乏VN滴度bb0 = 160。呼吸困难、住院和疾病严重程度与VN滴度升高显著相关。经常捐献恢复期血浆没有显著降低VN或IgG滴度。分析2814例无症状成人，73例抗ecd IgG滴度>= 1:50，与抗rbd和VN滴度呈强正相关。其中14例VN滴度>= 1:160，抗rbd滴度>= 1:1350。我们得出结论，抗rbd或抗ecd IgG滴度可以作为VN滴度的替代品，以确定合适的血浆供者。血浆抗rbd或抗ecd滴度>= 1:1350可提供COVID-19疾病防护的关键信息。
The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the urgent need for assays that detect protective levels of neutralizing antibodies. We studied the relationship among anti-spike ectodomain (anti-ECD), anti-receptor-binding domain (anti-RBD) IgG titers, and SARS-CoV-2 virus neutralization (VN) titers generated by 2 in vitro assays using convalescent plasma samples from 68 patients with COVID-19. We report a strong positive correlation between both plasma anti-RBD and anti-ECD IgG titers and in vitro VN titers. The probability of a VN titer of >= 160, the FDA-recommended level for convalescent plasma used for COVID-19 treatment, was >= 80% when anti-RBD or anti-ECD titers were >= 1:1350. Of all donors, 37% lacked VN titers of >= 160. Dyspnea, hospitalization, and disease severity were significantly associated with higher VN titer. Frequent donation of convalescent plasma did not significantly decrease VN or IgG titers. Analysis of 2814 asymptomatic adults found 73 individuals with anti-ECD IgG titers of >= 1:50 and strong positive correlation with anti-RBD and VN titers. Fourteen of these individuals had VN titers of >= 1:160, and all of them had anti-RBD titers of >= 1:1350. We conclude that anti-RBD or anti-ECD IgG titers can serve as a surrogate for VN titers to identify suitable plasma donors. Plasma anti-RBD or anti-ECD titers of >= 1:1350 may provide critical information about protection against COVID-19 disease.